SECTION I: ESTIMATION OF COSTS
| 1 | Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| ~20,000€=4×5,000€ (4 European patents) | |
| …in terms of product development | |
| Testing needs will be decided on a case by case basis (testing)163,200€ (development)
- 120,000€=24×5,000€ (24 person months of an experienced researcher, MSc or PhD)
- 43,200€=24×1,800€ (24 person months of an experienced developer)
|
|
| …in terms of mass production | |
| 10,000€=5×2,000€ (A cluster of 3-5 high performance PCs with up to 100 TB HDs with fast access and data protection but it depends on the content) | |
| … in terms of marketing | |
| - (standard cost of marketing for a specialized medical informatics software product) | |
| 2 | Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs | |||||
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | ||
| Fixed costs | 10,000€ | - | - | - | - | |
| Personnel | 163,200€ | - | - | - | - | |
| Other running costs | - | - | - | - | - | |
| Marketing costs | ? | ? | ? | ? | ? | |
| TOTAL EXPECTED COSTS | 173,200€ | - | - | - | - | |
| Price per Unit | ? | ? | ? | ? | ? | |
| Type of Unit | ? | |||||
| Number of Units | ? | ? | ? | ? | ? | |
| TOTAL Expected Revenues | ? | ? | ? | ? | ? | |
| CASH FLOW REQUIRED (REVENUES-COSTS) | ? | ? | ? | ? | ? | |
| TOTAL CAPITAL required for five years | ~200,000€ | |||||
SECTION 2: QUALITATIVE FACTORS
| 3 | Dimension of identified target groups |
| - Digital content providers, news agencies, cultural heritage organizations.- Search engine providers. | |
| 4 | Evaluation of financial Risks for R&D result |
| Low risks since development of product does not require high expenses. | |
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
| 1. European FundingDefine relevance of the product with the following potential funding sources and comment |
| 1. …2. …
3. … 4. … |
| 2. National Funding |
| 1. …2. …
3. … … |
| 3. Private funding |
| 1. …2. …
3. … … |
| 4. Other |
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
| Creation of spin-off. |
Decision of evaluation (Please keep only the appropriate)
- · The R&D has a high potential of exploitation
- · The R&D result needs minor revisions
- · The R&D result needs moderate revisions
- · The R&D result needs major revisions
- · The R&D result has no potential of exploitation
Costas Kotoulas
